Glycosaminoglycans (GAGs) are linear polysaccharides comprised of glucosamine/uronic acid-containing repeating disaccharides with different sulphation and uronic acid epimer patterns. 8 GAGs are covalently linked to proteins during their biosynthesis.
The proteins that carry GAG chains are known as proteoglycans.
Two major types of GAGs are heparan sulphate (HS) consisting of GlcN-GlcA/IdoA (glucuronic/iduronic acid) repeating disaccharide units and chondroitin sulphate (CS) consisting of GalN-GlcA/IdoA repeating disaccharide units. HS and CS GAGs are synthesized by all animal cells. Because their repeating disaccharides can have diverse sulphation and different repeating disaccharide GlcN-GlcA/IdoA or GalN-GlcA/IdoA patterns due to differential expressions of GAG biosynthetic enzymes in different animal cells, 1, 7, 9 the quantity and HS or CS disaccharide compositions are varying not only from cell to cell but also from tissues to tissues. 4, 10 The biological functions of proteoglycans are largely dependent on their GAG chains. 7, 11 Rapid turnover 11, 12 and structure diversity generated by both biosynthesis and post biosynthesis modification allow GAGs to promote or inhibit a myriad of signalling pathways, 11 such as fibroblast growth factor (FGF) and FGF receptor (FGFR) signalling pathway. [13] [14] [15] [16] [17] Indeed, it has been well documented that GAGs play critical roles in physiological and pathological processes in both human and animals. 4, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Properly sulphated GAGs are indispensable for their biological activities. Thus, it is highly desirable to have small molecules that disrupt GAG biosynthesis in cell culture conditions or in animal models to establish GAG structure/function relationship. At present, only sodium chlorate, an inhibitor of the universal sulphate donor 3-phospho-adenyl-5-phosphosulfate (PAPS), 28, 29 and D-xylosides, which act as artificial primers of GAG biosynthesis, [29] [30] [31] has such function.
Therefore, it is important to develop proper assays to screen for reagents that disrupt GAG biosynthesis.
All BLMs are positively charged molecules and cannot get inside of cells by free diffusion. 4 GAGs are present at the cell surface in the form of proteoglycans. Interestingly, proteoglycans are well-established cell surface endocytosis receptors. 32, 33 Therefore, we hypothesized that positively charged BLMA5 may interact with the negatively charged GAGs of proteoglycans on the cell surface for their cellular uptake. Indeed, by treating six different cell lines including a unique Chinese hamster ovary cell mutant defective in cell surface GAG biosynthesis (CHO745) with BLM A2, B2, A5 or combination of any two of them, 1 the cytotoxicity data suggested that GAGs might be involved in the cellular uptake of all BLMs. 1, 4 Since BLM has no optical properties, we have synthesized a series of small molecules with intrinsic fluorescence with or without positive charge, that is isothiouronium-or bromo-modified curcumin-pyrimidine analogs. 4 We found that only the positively charged curcumin-pyrimidine analogs have Golgi localization once inside of the cells. 34 As such, we assumed that BLMA5 might interfere with GAG biosynthesis in Golgi.
Changes in CS disaccharide compositions of proteoglycans in
BLM-treated rat model have been reported. 35 By using a novel stable isotope labelling coupled with LC/MS method, we found BLM inhibits both HS and CS sulphation in cancer cell lines. 4 In current study, human colon cancer cell lines HCT116 and HT29, human lung cancer cell lines H1299 and A549, a Lewis lung carcinoma-injected C57BL/6 mouse model were used to test if BLMA5 had the same effect. Wild-type Chinese hamster ovary cell line CHOK1, cell surface   GAG-deficient CHO cell line CHO 745 36 and 3-O-sulphotransferase-1-expressing CHOK1 cell line, CHO 3.1, 37 were also used to test how the cell surface GAGs were related to the cytotoxicity effects of BLMA5. Furthermore, by using flow cytometry-based cell surface FGF/FGFR/GAG binding assay plus stable isotope labelling coupled with LC/MS analysis, we demonstrated that BLMA5 inhibited glycosaminoglycan sulphation in the tumour tissues of the mouse model.
| MATERIAL S AND ME THODS

| Cell growth inhibition assay
The method was similar to the previously published one. 4 
| Flow cytometry analysis of cell surface GAG/ FGF/FGFR ternary complex formation
The method was similar to the previously published one. 37 BLMA5 (10 μmol/L, 2 hours; Tianjin Tai-he pharmaceutical), or 0.1% DMSO (Solarbio) treated A549 and HCT116 cells were collected by using phosphate-buffered saline (137 mmol/L NaCl, 2.7 mmol/L KCl, 
| The effects of different types of GAGs on the cytotoxicity induced by BLMA5 in cell culture
The method was similar to the previously published one. 4 Briefly, HCT116, A549, CHO 745 cells were seeded in 96-well plates. 
| The effects of sodium chlorate in cell culture media on the cytotoxicity induced by BLMA5
The method was similar to the previously published one. 4 Briefly, sulphation was inhibited by sodium chlorate treatment. 28 
| Purification of GAGs from control and BLMA5 treated cells
The method is the same as described previously. 4 Briefly, control cells (0.1% DMSO treated) and BLMA5 treated cells with a final DMSO concentration of 0.1% were used for GAG preparations.
GAGs were then extracted from the control and BLMA5 treated cells.
| Establishing C57BL/6 mouse model of lung tumours
All mice were treated in accordance with the regulations approved by the Animal Ethics Committee of Ocean University of China, which were performed in accordance with National Institutes of Health guidelines.
The method is similar to that published in previous study. 38 LLC cells (Type culture collection of the Chinese academy of sciences) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal bovine serum plus ampicillin and streptomycin routinely, and incubated in 5% CO 2 at 37°C. The LLC cells (1 × 10 7 cells/mL) were then injected into C57BL/6 mice to prepare enough tumour cells to establish C57BL/6 mouse model of lung tumours. Briefly, the tumour tissues from Lewis lung carcinoma mice were triturated and the tumour cell suspensions were then prepared in that the cell concentration was adjusted to 1 × 10 7 cells/mL, and 0.2 mL cell suspensions were injected subcutaneously into the armpit of right anterior superior limbs of female C57BL/6 mice (National Institute for the Control of Biological and Pharmaceutical Products) to establish the lung tumour model, the mice were 6-8 week old (weight 18.6 ± 0.5 g). Three days later, the mice were randomized into two groups (16 mice per group), a treatment group injected with BLMA5 in saline (1.2 mg/kg) into the hind leg muscle every 3rd day.
A control group injected with the same volume of saline every 3rd day. All treatments lasted for 28 days. Mice were killed, and lung tumours were harvested and stored at −80°C until used.
| Purification of GAGs from lung tumours
Tumours were defatted before GAG purification. For short, tumours were weighed and homogenized in cold acetone and shook at shaking table for 24 hours. The acetone was removed by aspiration after centrifugation at 3939 g for 15 minutes. Methanol and chloroform were then added to pellets while stirring to a final ratio of 1:2 (CH 3 OH:CHCl 3 v/v) and left overnight at room temperature followed by centrifugation at the same condition to obtain the defatted tumour tissues, which were washed twice with ethanol and dried at room temperature. The defatted tissues were suspended in 10 mL 0.25 mol/L NaCl buffer (0.25 mol/L NaCl, pH 6.0, 20 mmol/L NaAc, 0.01% Triton X-100) before protease digestion using the identical GAG purification procedure described above.
| Generating HS and CS disaccharide by enzymatic digestion
The method is the same as described previously. 4 Briefly, GAGs were divided into two parts, one for HS disaccharide analysis and the other for CS disaccharide analysis. For HS digestions, GAGs were incubated with 0.33 mU each of heparin lyase I, II and III. For CS digestions, GAGs were incubated in digestion solution containing chondroitinase ABC. Digestion was monitored by using a Spectra MAX M2 plate reading spectrophotometer.
| PMP labelling and LC/MS analysis
The method is the same as described previously. 4 Briefly, PMP 
| BLMA5 treatment changed FGF/FGFR/GAG binding on the cell surfaces of A549 and HCT116 cells detected by flow cytometry
We have previously developed a flow cytometry-based cell surface binding assay that allows to measure the interaction between cell surface GAGs with fluorescence-labelling GAG binding proteins, 39 We reasoned that this assay would allow us to test if BLMA5 could change the cell surface GAG structures. Fibroblast growth factors (FGFs) comprise a structurally related family of 22 molecules, and bind four high affinities, liganddependent FGF receptor tyrosine kinase molecules (FGFR1-4). 40 FGF signalling activity depends on the affinity among the FGF, FGFR and specific GAG structures. 41 We performed the flow cytometry assay of FGF/FGFR/GAG ternary complex formation (See details in Section 2). In brief, both A549 and HCT116 cells were treated with 10 μmol/L BLMA5 for 2 hours before the assay. The protein A-Alexa Fluor 488 was added to control cells to set up the background cell fluorescence level (Figure 2 (Figure 2A,B FGFR2b , the apparent right shift of the blue peaks). Most importantly, after BLMA5-treatment, the fluorescent intensities and profiles of all FGF/ FGFR/GAG ternary complex (BLMA5 treated, turquoise peaks) were different from of that control (purple peaks) in both A549 ( Figure 1A) and HCT116 ( Figure 1B) cells. As is known to all, FGF7 not only binds to HS 42 but also binds to CS-B or dermatan sulphate, 43 
| Cell surface GAGs were responsible for getting BLMA5 inside cells to exert its cytotoxicity
Sodium chlorate is the reversible sulphation inhibitor, 44 and it was used to treat HCT116, A549 and CHO 745 cells to expound whether GAG sulphation was involved in the cytotoxicity of BLMA5 through endocytosis ( Figure 3A-C) . Different concentrations of sodium chlorate alone (from 0.016 to 10 mmol/L) had no cytotoxicity as shown in Figure 3A -C. However, the cytotoxicity of BLMA5 towards HCT116 and A549 cells was significantly reduced after adding different concentrations of sodium chlorate. On the contrary, at the same concentration, the cytotoxicity of BLMA5 to CHO 745 cells lacking GAG on the cell surface was significantly increased. Thus, sulphation of GAG contributed to the uptake and cytotoxicity of BLMA5 for both A549 and HCT116 cells.
To further confirm the involvement of cell surface GAG, different types of GAGs were added to cell culture medium to compete with GAGs on the cell surface for binding to BLMA5. As shown in Figure 3D 
| Changes of CS and HS disaccharides in A549 and HCT116 cells
The data in Figures 2 and 3 indicated BLMA5 treatment changed GAG structures of A549 and HCT116 cells. However, detailed GAG structure characterization is required to demonstrate such changes.
In GAG research field, CS and HS disaccharide compositional analysis is used for such purpose. To facilitate quantitative comparison of GAG disaccharide compositions from different cell types, we have previously tagged the reducing end of enzyme-digested disaccharides with aniline-containing normal and stable isotopes. 4, 45 Because different isotope tags have no effect on LC retention times but are discriminated by MS analysis, differentially isotope-tagged disaccharides can be compared simultaneously by LC/MS. 4, 45, 46 To test how BLMA5 changed biosynthesis and metabolism of GAGs, A549 and HCT116 cells were treated with BLMA5 either at high concentration (80 μmol/L) for a short period of time (4 hours; TA B L E 2 Molecular masses for GAG disaccharides detected in cancer cells exactly observed in the MS data ( Figure 4 ). We then summarized all the molecular mass over charge (m/z) for the stable isotope labelled GAGs disaccharides of BLMA5-treated or non-BLMA5-treated cancer cells in Table 2 .
| The CS and HS disaccharide compositions from cancer cells
In this study, each disaccharide was separated by using a solvent gradient (See details in Section 2). The ion current intensities of the stable isotope labelled disaccharides were increased with the increase of acetonitrile concentrations during the LC run. Therefore, we used commercial disaccharides to obtain the response factor for each disaccharide using the same method we reported previously. 4, 11 Then, the proportion of each GAGs disaccharide was calculated based on MS data. The results were shown in Figure 5A -D.
First of all, CS disaccharide compositions were similar in both A549 and HCT116 control cells; however, the HS disaccharide compositions were different as the D0A6 was present in HCT116 cells but was undetectable in A549 cells ( Figure 5A-D) . Secondly, the percentage of CS D0a4 disaccharide was increased in the HCST BLMA5-treated A549 cells, whereas D0a4 disaccharide was disappeared in the LCLT BLMA5-treated HCT116 cells. Thirdly, HS disaccharide compositions in either HCST or LCLT BLMA5 treatment conditions were totally different from that of the control A549 and HCT116 cells, that is the proportion of non-sulphated HS disaccharides (D0A0) were increased significantly, but the proportion of all sulphated HS disaccharides were decreased, which indicated that BLMA5 suppressed HS sulphation during GAG biosynthesis. In contrast, BLMA5 treatment changed CS disaccharide compositions. Figure 6B , respectively. The fold quantity differences in each CS ( Figure 6C ) and HS ( Figure 6D ) disaccharides from lung tumours between BLM-treated and saline-treated mice were calculated based on the data presented in Figure 6A ,B, that is the PMP-labelled disaccharide% from lung tumours of BLMA5-treated C57BL/6 mice was divided by the D5PMP-labelled disaccharide% from lung tumours of saline-treated C57BL/6 mice. The CS D0a6
and D0a10 disaccharides ( Figure 6C ) were significantly decreased in lung tumours of BLMA5-treated mice. Overall sulphation of HS disaccharides ( Figure 6D ) was also decreased in BLMA5-treated mice. Thus, the data in Figure 6A -D revealed that BLMA5 treatment reduced both CS and HS sulphation in the lung tumours of C57BL/6 mouse model significantly.
| D ISCUSS I ON
We summarized our overall results in the In Figure 5B , BLMA5 treatment led to a dramatic increase in CS D0a6 in HCT116 cells; however, D0a6 in BLMA5 treated LLC cells ( Figure 6A ) was significantly reduced, which raised the question how could BLMA5 have opposite effects in these two cell lines. cell-based assays. 41, 48 Among all the GAGs, heparin is the mostly charged and also has the rare 3-O-sulphated sequences that are critical for its anticoagulant activities. Heparin is the most active GAG in most of biological tests but with exceptions. 49 Indeed, the data in Figure 4 showed that heparin appeared less effective than HS in inhibiting BLMA5-induced cytotoxicity, indicating HS was involved in the uptake of BLMA5. 
Control BLM A5 treatment
With the same genetic background, BLMA5 showed little toxicity even at 160 μmol/L in the cell surface GAG-deficient CHO 745 cells compared to that of CHO K1 and CHO 3.1 cells. These experimental results indicated that GAGs may participate in the uptake of BLMA5 through a cell surface GAG-dependent manner.
The occurrence of pulmonary fibrosis induced by bleomycin is a major clinical problem. [50] [51] [52] Resistance to bleomycin in cancer cell lines is characterized by prolonged doubling time, reduced DNA damage and evasion of G2/M arrest and apoptosis, 52 but CHO 745 cells have the same doubling time as that of CHO K1 and CHO 3.1 cells. 1, 36, 53 Based on these results, we propose that GAGs in lung epithelial cells may help cells to uptake BLMA5. We have established a BLMA5-induced mouse pulmonary fibrosis model and this speculation is under investigation.
Glycosaminoglycan assembly in the Golgi is sensitive to drug treatment and a variety of environmental factors because there is no template for GAG biosynthesis. However, the drug and environmental induced structural changes of GAGs are an understudied area due to lack of proper methods. Therefore, the flow cytometry-based cell surface FGF/FGFR/GAG binding assay plus the method of stable isotope labelling coupled with LC-MS analysis of GAG disaccharide compositions used in current study should be effective tools to search for small molecule therapeutics that alter GAG biosynthesis in future. 4,54,55
| Statistical analysis of data
All statistical calculations were done using IBM SPSS Statistics 21.
All data are represented as the mean ± SD t test was used to determine the possible significant differences (P < .05) of indicators between control group and treatment groups.
